跨国药企洞察|默沙东终止康方2亿美元合作项目,跨国药企如何“优中选优”?

动脉新医药
Aug 12

编者按:全球视野下的跨国药企深度洞察——创新、博弈与中国答卷在全球医药产业发展的宏大叙事中,跨国药企始终扮演着关键角色——他们既是科学前沿的探索者,也是大多市场规则的塑造者,更是各国医疗生态的重要参与者。从FDA到EMA再到NMPA ,从成熟市场到新兴市场,跨国药企的战略抉择不仅关乎企业自身的兴衰,更深刻影响着全球患者的健康福祉。而在这一版图中,中国市场也正从“可选项”到“必选项”再升级为“决胜场...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10